BR112016007526A2 - formulação de tratamento contra hiv de atazanavir e cobicistat - Google Patents

formulação de tratamento contra hiv de atazanavir e cobicistat

Info

Publication number
BR112016007526A2
BR112016007526A2 BR112016007526A BR112016007526A BR112016007526A2 BR 112016007526 A2 BR112016007526 A2 BR 112016007526A2 BR 112016007526 A BR112016007526 A BR 112016007526A BR 112016007526 A BR112016007526 A BR 112016007526A BR 112016007526 A2 BR112016007526 A2 BR 112016007526A2
Authority
BR
Brazil
Prior art keywords
cobicistat
atazanavir
treatment formulation
hiv treatment
formulations
Prior art date
Application number
BR112016007526A
Other languages
English (en)
Other versions
BR112016007526A8 (pt
Inventor
Nikfar Faranak
Tao Jing
Kumar Kottala Niranjan
May Yue Koo Otilia
A Varia Sailesh
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016007526(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112016007526A2 publication Critical patent/BR112016007526A2/pt
Publication of BR112016007526A8 publication Critical patent/BR112016007526A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se às formulações dos compostos contra hiv atazanavir e cobicistat, e os métodos de tratamento utilizando estas formulações, são apresentadas.
BR112016007526A 2013-10-07 2014-10-06 formulação de comprimido bicamada de dois fármacos antirretrovirais úteis contra o hiv, comprimido, seu método de produção e uso BR112016007526A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887574P 2013-10-07 2013-10-07
PCT/US2014/059310 WO2015054133A1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat

Publications (2)

Publication Number Publication Date
BR112016007526A2 true BR112016007526A2 (pt) 2017-08-01
BR112016007526A8 BR112016007526A8 (pt) 2020-03-03

Family

ID=51743576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007526A BR112016007526A8 (pt) 2013-10-07 2014-10-06 formulação de comprimido bicamada de dois fármacos antirretrovirais úteis contra o hiv, comprimido, seu método de produção e uso

Country Status (27)

Country Link
US (2) US20160038502A1 (pt)
EP (2) EP3054926B1 (pt)
JP (2) JP6574415B2 (pt)
KR (1) KR102286386B1 (pt)
CN (1) CN106029058A (pt)
AU (1) AU2014332200B2 (pt)
BR (1) BR112016007526A8 (pt)
CA (1) CA2926650A1 (pt)
CL (1) CL2016000787A1 (pt)
CY (1) CY1121105T1 (pt)
DK (2) DK3421033T3 (pt)
EA (1) EA031172B1 (pt)
ES (2) ES2693580T3 (pt)
HR (2) HRP20221126T1 (pt)
HU (1) HUE059757T2 (pt)
IL (1) IL244881B (pt)
LT (2) LT3054926T (pt)
MX (1) MX368268B (pt)
MY (1) MY178960A (pt)
PE (1) PE20160596A1 (pt)
PL (2) PL3054926T3 (pt)
PT (2) PT3421033T (pt)
RS (2) RS57882B1 (pt)
SA (1) SA516370891B1 (pt)
SG (1) SG11201602501VA (pt)
SI (2) SI3421033T1 (pt)
WO (1) WO2015054133A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP3496719B1 (en) * 2016-08-08 2023-06-14 Hetero Labs Limited A multi-class anti-retroviral composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) * 2000-03-14 2003-09-09 レストラゲン，インコーポレイテッド 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
BRPI0717171B1 (pt) * 2006-09-25 2023-10-17 Archer Daniels Midland Company Material superabsorvente
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT

Also Published As

Publication number Publication date
RS63570B1 (sr) 2022-10-31
LT3421033T (lt) 2022-11-10
CL2016000787A1 (es) 2016-11-25
DK3421033T3 (da) 2022-10-10
RS57882B1 (sr) 2019-01-31
DK3054926T3 (en) 2018-10-29
PT3421033T (pt) 2022-09-23
BR112016007526A8 (pt) 2020-03-03
SI3421033T1 (sl) 2022-11-30
EA201690594A1 (ru) 2016-09-30
HRP20181582T1 (hr) 2018-11-30
CN106029058A (zh) 2016-10-12
EA031172B1 (ru) 2018-11-30
KR102286386B1 (ko) 2021-08-05
JP6574415B2 (ja) 2019-09-11
EP3421033A1 (en) 2019-01-02
SA516370891B1 (ar) 2018-08-08
AU2014332200B2 (en) 2018-10-04
MX2016004078A (es) 2016-06-06
HUE059757T2 (hu) 2023-01-28
LT3054926T (lt) 2018-11-12
HRP20221126T1 (hr) 2022-11-25
KR20160060764A (ko) 2016-05-30
CY1121105T1 (el) 2019-12-11
EP3054926B1 (en) 2018-07-25
ES2927484T3 (es) 2022-11-07
PE20160596A1 (es) 2016-06-15
ES2693580T3 (es) 2018-12-12
PL3054926T3 (pl) 2018-12-31
CA2926650A1 (en) 2015-04-16
SI3054926T1 (sl) 2018-10-30
EP3054926A1 (en) 2016-08-17
MY178960A (en) 2020-10-26
EP3421033B1 (en) 2022-07-27
AU2014332200A1 (en) 2016-05-19
US20160038502A1 (en) 2016-02-11
IL244881A0 (en) 2016-05-31
US20190358240A1 (en) 2019-11-28
MX368268B (es) 2019-09-26
SG11201602501VA (en) 2016-04-28
JP2019011334A (ja) 2019-01-24
JP2016532649A (ja) 2016-10-20
WO2015054133A1 (en) 2015-04-16
PL3421033T3 (pl) 2022-10-03
PT3054926T (pt) 2018-10-26
IL244881B (en) 2021-12-01

Similar Documents

Publication Publication Date Title
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112017001796A2 (pt) composições de flagelina e seus usos
EA201890201A1 (ru) Антибактериальные соединения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
PH12017500836A1 (en) Transdermal formulations
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112016007526A2 (pt) formulação de tratamento contra hiv de atazanavir e cobicistat
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112018009946A2 (pt) pró-fármacos de ácido nucleico
BR112016028192A2 (pt) gerritdina g. schoonus-gerritsma
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
BR112018007954A2 (pt) moduladores da interação sestrina-gator2 e usos destes
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements